Send to:

Choose Destination
See comment in PubMed Commons below
Am J Cardiol. 2014 Sep 15;114(6):849-55. doi: 10.1016/j.amjcard.2014.06.015. Epub 2014 Jul 2.

Efficacy and cost-effectiveness of dabigatran etexilate versus warfarin in atrial fibrillation in different age subgroups.

Author information

  • 1Clinical Development & Medical Affair, Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim am Rhein, Germany; Center of Thrombosis and Hemostasis, Johannes Gutenberg University, Medical Center, Mainz, Germany.
  • 2Modeling and Simulation, Evidera, Bethesda, Maryland.
  • 3Clinical Development & Medical Affair, Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim am Rhein, Germany; Faculty of Medicine Mannheim, University of Heidelberg, Mannheim, Germany.
  • 4Health Economics and Outcomes Research, Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut.
  • 5Clinical Development & Medical Affair, Boehringer Ingelheim Pharma GmbH & Co KG, Ingelheim am Rhein, Germany.
  • 6Modeling and Simulation, Evidera, Bethesda, Maryland. Electronic address:


This study aims to estimate the cost-effectiveness of dabigatran 150 mg twice daily versus warfarin for stroke and systemic embolism risk reduction in patients with nonvalvular atrial fibrillation initiating treatment before age 75 (<75), at or after age 75 (≥ 75), and the overall population (All) from a US Medicare payer perspective. Clinical event rates by age cohort with dabigatran or warfarin for safety-on-treatment and intent-to-treat populations were estimated from Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY). An economic model was adapted using these data to evaluate the impact of starting age on clinical and economic outcomes. Costs were obtained from Medicare payment schedules and utilities from publications. Model outputs included event rates, costs, quality-adjusted life-years, and incremental cost-effectiveness ratios. The RE-LY analysis shows that the <75 cohort has lower rates of all events than the ≥ 75 cohort; versus warfarin, dabigatran performed better in main efficacy and safety in all age cohorts with the exception of extracranial hemorrhage in the ≥ 75 cohort. The clinical event costs avoided per patient for dabigatran were $1,100, $135, and $713 for cohorts <75, ≥ 75, and All, respectively. Extrapolating over a lifetime horizon, the model found that dabigatran resulted in lower rates of stroke and intracranial hemorrhage and higher rates for extracranial hemorrhage versus warfarin for all age cohorts. Lifetime quality-adjusted life-years and costs were higher for dabigatran than warfarin, resulting in incremental cost-effectiveness ratios of $52,773, $65,946, and $56,131 for cohorts <75, ≥ 75, and All, respectively. In conclusion, dabigatran was cost-effective versus warfarin in US patients with atrial fibrillation regardless of age of treatment initiation.

Copyright © 2014 The Authors. Published by Elsevier Inc. All rights reserved.

[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk